Novavax submits biologics license application to South Korea

Gaithersburg, Maryland, November 17, 2021/PRNewswire/ - Novavax, Inc.

Stanley C.

In cooperation with Novavax, SK bioscience initiated a rolling submission process to MFDS for NVX-CoV2373 in April this year

The existing production and licensing cooperation between Novavax and SK biocience aims to provide broad and fair access to NVX-CoV2373 through COVAX factory facilities in Korea and globally

Jaeyong Ahn, CEO of SK bioscience, said: "Novavax protein-based vaccines will become the new cornerstone of the

Novavax recently announced that its vaccine has been licensed in Indonesia

About NVX-CoV2373 Phase III Trial

NVX-CoV2373 is being evaluated in two key Phase 3 trials: a trial conducted in the UK showed that the vaccine is 96.

About NVX-CoV2373

NVX-CoV2373 is a protein-based vaccine candidate, designed and synthesized based on the genetic sequence of the first SARS-CoV-2 (the disease-causing virus of new coronary pneumonia)

Novavax's new crown vaccine is packaged in a ten-dose vial as a ready-to-use liquid formulation

About Matrix-M™ adjuvant 

Novavax's patented Matrix-M™ adjuvant based on saponin can stimulate antigen-presenting cells to enter the injection site, enhance the antigen presentation of local lymph nodes, thereby enhancing the immune response, and has shown a strong and well-tolerated effect

About Novavax

Novavax, Inc.

For more information, please visitor contact us via Twitter and LinkedIn

Forward-looking statements

The statements in this article regarding the following are forward-looking statements: Novavax's future situation, operating plans and prospects, partnerships, continuous development of NVX-CoV2373 and other Novavax vaccine candidates, the scope, timing and results of future regulatory filings and measures , And the expected role of Novavax in the fight against the new crown epidemic